SHANGHAI – October 29, 2026 -- United Imaging Healthcare (688271.SH) posted revenue of RMB 10.58 billion for the first nine months of 2026, up 19.43% year-on-year, as international sales grew 50.30%.
Third-quarter revenue reached RMB 3.53 billion. Net profit attributable to shareholders rose 13% year-on-year to RMB 138 million.
International sales reach 28.31% of group revenue
Overseas revenue totaled RMB 3.00 billion in the period. Its share of total revenue rose 5.82 percentage points from a year earlier to 28.31%.
Europe revenue grows nearly 30% on 850-plus deliveries
Cumulative deliveries in Europe exceeded 850 systems, with high-end imaging equipment deployed in more than half of EU member states. A regional team of more than 160 employees supports the business. In North America, the company expanded relationships with integrated delivery networks and secured eligibility under framework agreements.
Asia-Pacific revenue more than doubles
Revenue in Asia-Pacific increased by more than 100% year-on-year. Several high-end MRI systems were installed within Singapore Health Services (SingHealth), and PET/CT installations in Australia continued to rise. Japan's first uMI Panvivo PET/CT system was installed at Saitama Central Clinic.
In China, market share rose 2.2 percentage points year-on-year, backed by progress in high-end imaging, interventional systems and radiotherapy.
Regulatory approvals reach 170 in China, 84 CE and 79 FDA
As of September 30, 2026, 170 products held approval from China's National Medical Products Administration, 84 had CE certification and 79 had U.S. FDA 510(k) clearance. The first nine months added 18 NMPA approvals, 14 CE certifications and 21 FDA clearances. Eight products were recognized under China's national innovative medical device program.
More than 40 AI-enabled devices had received FDA clearance. The company completed development and deployment of intelligent technology platforms across all product lines.
Patent filings top 10,800 with more than 5,700 granted
Cumulative patent applications exceeded 10,800, of which more than 80% were invention patents. Granted patents totaled over 5,700.
Products serve more than 100 countries and regions and reach over 17,000 medical and research institutions. Cumulative system deliveries exceeded 41,000, supported by more than 1,100 service engineers worldwide.